Shots:

• The P-I/II Stellar trial involve assessing QR-421a in 20 patients with usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations for 24mos.
• Results: QR-421 demonstrated benefit on multiple measures of vision- including best-corrected visual activity (BCVA)- static perimetry- and retinal imaging (OCT) and was well-tolerated with no observed SAEs and inflammation
• The company plans to initiate two pivotal P-II/III trials in early-moderate and advanced patients by the end of 2021

 ­ Ref: ProQR | Image: EyeWire News